Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amulet IDE Trial Supports Abbott’s New LAA Closure Device

Executive Summary

Results of the trial showed Amplatzer Amulet was superior to Boston Scientific’s Watchman for left-atrial appendage closure and noninferior for safety and effectiveness.

You may also be interested in...



Cardio Catch-Up: Medtech Innovation Takes Center Stage At TCT 2022

This edition of Medtech Insight’s regular round-up of heart-tech news covers some highlights of this years’ Transcatheter Cardiovascular Therapeutics (TCT) meeting in September, including the latest trials of Abbott's Amulet left-atrial appendage closure device and Medtronic's Intrepid transcatheter mitral valve replacement.

Cardiovascular Catch-Up: Abbott, Medtronic, Boston Scientific Stay Hot During Summer

June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.

FDA Approves Abbott’s Amplatzer Amulet LAA Occluder To Compete With Boston Scientific’s Watchman

Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel